We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

0 hedge funds and large institutions have $0 invested in Sciclone Pharmaceuticals Inc in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 128 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 129 → 0 (-129)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $394M → $0 (-$394M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 128

Holders
–
Holders Change
-129
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
128
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$82.1M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$33.3M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$32.3M
4
GP
GLG Partners
United Kingdom
-$29M
5
State Street
State Street
Massachusetts
-$18.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
– -$3.44M -307,087 Closed
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
– -$3.42M -305,279 Closed
Goldman Sachs
28
Goldman Sachs
New York
– -$3.13M -279,225 Closed
Skandinaviska Enskilda Banken (SEB)
29
Skandinaviska Enskilda Banken (SEB)
Sweden
– -$2.87M -256,200 Closed
TCIM
30
TIAA CREF Investment Management
New York
– -$2.84M -253,489 Closed
Allianz Asset Management
31
Allianz Asset Management
Germany
– -$2.61M -232,872 Closed
PAM
32
Panagora Asset Management
Massachusetts
– -$2.53M -226,098 Closed
Ohio Public Employees Retirement System (OPERS)
33
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$2.48M -221,421 Closed
Citigroup
34
Citigroup
New York
– -$2.21M -197,565 Closed
PPA
35
Parametric Portfolio Associates
Washington
– -$2.02M -180,436 Closed
GC
36
Guggenheim Capital
Illinois
– -$1.9M -169,952 Closed
UBS Group
37
UBS Group
Switzerland
– -$1.88M -168,059 Closed
SG Americas Securities
38
SG Americas Securities
New York
– -$1.88M -167,417 Closed
Invesco
39
Invesco
Georgia
– -$1.87M -167,178 Closed
CS
40
Credit Suisse
Switzerland
– -$1.46M -130,424 Closed
BPM
41
Bowling Portfolio Management
Ohio
– -$1.43M -127,873 Closed
Russell Investments Group
42
Russell Investments Group
United Kingdom
– -$1.37M -121,942 Closed
Barclays
43
Barclays
United Kingdom
– -$1.27M -113,303 Closed
GCP
44
GSA Capital Partners
United Kingdom
– -$1.24M -110,500 Closed
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
– -$1.21M -107,645 Closed
California Public Employees Retirement System
46
California Public Employees Retirement System
California
– -$1.13M -100,634 Closed
MERSOM
47
Municipal Employees' Retirement System of Michigan
Michigan
– -$1.09M -97,450 Closed
Legal & General Group
48
Legal & General Group
United Kingdom
– -$1.06M -94,464 Closed
AA
49
ALPS Advisors
Colorado
– -$1.05M -93,978 Closed
TA
50
Teachers Advisors
New York
– -$1.03M -92,400 Closed
1
2
3 4 5

SCLN Hedge Fund Activity: Q4 2017 in Review

0 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2017, worth a combined $0 — down 100% from $394M a quarter earlier.

Sellers outnumbered buyers: 128 funds closed out of SCLN and 0 opened new positions — a net loss of 128 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $82.1M sold.

  • 0 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2017, down from 129 in Q3 2017.
  • Funds reported $0 of Sciclone Pharmaceuticals Inc stock for Q4 2017, down 100% quarter-over-quarter.
  • 0 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2017 and 128 closed out, a net change of -128 holders.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2017 was BlackRock, an estimated $82.1M sold.

Based on aggregated 13F filings for Q4 2017.